Thyroid Dysfunction Related to the Antiangiogenic VEGFR2-Binding Monoclonal Antibody Ramucirumab: A Series of 14 Cases and a Descriptive Study

• Published in: Biological & pharmaceutical bulletin 2020/04/01, Vol.43(4), pp.752-756
• Main Authors: Dote, Satoshi, Yamaguchi, Daisuke, Hira, Daiki, Noda, Satoshi, Kobayashi, Yuka, Terada, Tomohiro
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; Angiogenesis Inhibitors - adverse effects; anti-vascular endothelial growth factor monoclonal antibody; Antibodies, Monoclonal, Humanized - adverse effects; Antineoplastic Agents - adverse effects; Autoantibodies; Chemotherapy; Electronic medical records; Female; Humans; Hypothyroidism; Hypothyroidism - blood; Hypothyroidism - chemically induced; Immunotherapy; Male; Middle Aged; Monoclonal antibodies; Patients; Protein-tyrosine kinase; Ramucirumab; Thyroid; Thyroid diseases; thyroid dysfunction; Thyroid gland; Thyroid-stimulating hormone; Thyrotropin - blood; Thyroxine; Toxicity; Vascular endothelial growth factor; Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors; Vascular Endothelial Growth Factor Receptor-2 - immunology
• ISSN: 0918-6158; 1347-5215
• DOI: 10.1248/bpb.b19-01071

Hypothyroidism is a well-established toxicity of small-molecule anti-vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors. However, its association with anti-VEGF biologics is uncertain. The aim of this study was to investigate the incidence, time course, clinical features, and severity of thyroid dysfunction in patients receiving ramucirumab (an antiangiogenic VEGF receptor 2-binding monoclonal antibody). After retrospectively reviewing electronic medical records from September 2015 to December 2018 at Kyoto-Katsura Hospital, we identified 38 patients who received ramucirumab and had thyroid function testing available to review (case series). We also evaluated the change of thyroid-stimulating hormone (TSH) level during ramucirumab chemotherapy in 16 out of 38 patients who were regularly confirmed TSH (descriptive study). A total of 14 (36.8%) patients developed thyroid dysfunction (TSH >10 mU/L) after ramucirumab chemotherapy. Thyroid autoantibodies were detected in one of the 10 patients (10.0%) who were tested for thyroid autoantibodies. The median time to onset of thyroid dysfunction after ramucirumab initiation was 275 (range, 63–553) days. Levothyroxine replacement was needed in 10 (71.4%) patients. Sixteen patients had thyroid function regularly monitored; the mean TSH level was significantly increased after ramucirumab chemotherapy compared with that at baseline (10.7 ± 10.0 mU/L vs. 4.1 ± 2.8 mU/L; p